Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 2/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 17/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL230553 | 1.00 | CXCR4 (0.51) | CXCR4HRH4MAPK8HRH3 | |
| SCHEMBL4110591 | 0.97 | CXCR4 (0.50) | CXCR4HRH4MAPK8HRH3 | |
| SCHEMBL230622 | 0.96 | CXCR4 (0.49) | CXCR4HRH4MAPK8 | |
| SCHEMBL229092 | 0.94 | CXCR4 (0.53) | CXCR4HRH4MAPK8HRH3 | |
| SCHEMBL229091 | 0.94 | CXCR4 (0.53) | CXCR4HRH4MAPK8HRH3 | |
| SCHEMBL2007558 | 0.92 | CXCR4 (0.47) | CXCR4HRH4MAPK8 | |
| SCHEMBL14391723 | 0.92 | CXCR4 (0.47) | CXCR4HRH4MAPK8 | |
| SCHEMBL2007560 | 0.92 | CXCR4 (0.47) | CXCR4HRH4MAPK8 | |
| SCHEMBL4105351 | 0.92 | CXCR4 (0.47) | CXCR4HRH4MAPK8 | |
| SCHEMBL4105357 | 0.92 | CXCR4 (0.47) | CXCR4HRH4MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1993584-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPHTHALMIC DISEASE | Allergan, Inc. (US) | 2008-11-26 | — | — | EP | claimed |
| WO-2008029276-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPHTHALMIC DISEASE | ALLERGAN, INC. (US) | 2008-03-13 | — | — | WO | claimed |
| US-20070203089-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPHTHALMIC DISEASE | ALLERGAN, INC. | 2007-08-30 | — | — | US | claimed |
| EP-2407171-A2 | Compositions and methods for the treatment of ophthalmic disease | Allergan, Inc. (US) | 2012-01-18 | — | — | EP | disclosed |
| US-20120003275-A1 | Compositions and Methods for the Treatment of Ophthalmic Disease | ALLERGAN, INC. | 2012-01-05 | — | — | US | disclosed |
| EP-2397148-A2 | Compositions and methods for the treatment of ophthalmic disease | Allergan, Inc. (US) | 2011-12-21 | — | — | EP | disclosed |
| US-7964191-B2 | Compositions and methods for the treatment of ophthalmic disease | ALLERGAN, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| EP-1993584-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPHTHALMIC DISEASE | Allergan, Inc. (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2008029276-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPHTHALMIC DISEASE | ALLERGAN, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| US-20070203089-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPHTHALMIC DISEASE | ALLERGAN, INC. | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120003275-A1 | Compositions and Methods for the Treatment of Ophthalmic Disease | CXCL12, CXCR4, PDE6C | CXCR4 2/4885HRH4 2600/4885MAPK8 3375/4885 |
| US-20070203089-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPHTHALMIC DISEASE | CXCL12, CXCR4, PDE6C | CXCR4 2/4885HRH4 2600/4885MAPK8 3375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.